ProMIS Neurosciences (PMN) Stock Price, News & Analysis

Company Overview

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Key Stats

• Today's Range: C$5.98 to C$6.49
• 50-Day Range: C$6.00 to C$6.00
• 52-Week Range: C$3.34 to C$11.10
• Volume: 19,701 shs
• Average Volume: 3,327 shs
• Market Capitalization: C$51.48 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PMN Stock Analysis - Frequently Asked Questions

How have PMN shares performed this year?

ProMIS Neurosciences' stock was trading at C$6.00 at the beginning of the year. Since then, PMN stock has increased by 0.0% and is now trading at C$6.00.
View the best growth stocks for 2024 here.

How do I buy shares of ProMIS Neurosciences?

Shares of PMN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of ProMIS Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ProMIS Neurosciences investors own include CRISPR Therapeutics (CRSP), Aurora Cannabis (ACB), Keurig Dr Pepper (KDP), Biocept (BIOC), Onconova Therapeutics (ONTX), Spectra7 Microsystems (SEV) and TherapeuticsMD (TXMD).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: TSE:PMN
• Previous Symbol: TSE:AMF
• CUSIP: N/A
• CIK: N/A
• Web: www.promisneurosciences.com
• Phone: +1-416-8476898
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($3.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-20,930,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -837.71%
• Return on Assets: -168.33%

Debt

• Debt-to-Equity Ratio: 108.33
• Current Ratio: 0.51
• Quick Ratio: 1.30

Sales & Book Value

• Annual Sales: C$7,558.00
• Price / Sales: 6,811.33
• Cash Flow: C$0.43 per share
• Price / Cash Flow: 14.07
• Book Value: C($0.72) per share
• Price / Book: -8.33

Miscellaneous

• Outstanding Shares: 8,580,000
• Free Float: N/A
• Market Cap: C$51.48 million
• Optionable: Not Optionable
• Beta: 1.19